Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
ChinaIPO:
20 September 2017Website:
http://www.zailaboratory.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 20:56:15 GMTDividend
Analysts recommendations
Institutional Ownership
ZLAB Latest News
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has confirmed that senior management will be attending investor conferences in May and June 2024, including the J.P. Morgan 20th Annual Global China Summit Panel Discussion in Shanghai, China on May 23, 2024, and the Jefferies Global Healthcare Conference Fireside Chat in New York, New York on June 5, 2024.
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from preclinical studies highlighting the therapeutic potential of ZL-1310, the company's global next-generation antibody-drug conjugate (ADC) program. The preclinical profile of ZL-1310 will be the focus of a poster presentation at the European Lung Cancer Congress 2024 (ELCC 2024), scheduled for March 20-23, 2024 in Prague, Czech Republic. ZL-1310 is a novel a.
Zai Lab Limited (ZLAB) Q4 2023 Earnings Call Transcript
Zai Lab Limited Unsponsored ADR (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zai Lab Limited is a biotech company that acts as a powerful partner for other biotechs to launch drug candidates in China. They currently distribute four drugs in mainland China and have a pipeline of cancer therapies awaiting approval. ZLAB has a strong financial position with significant cash reserves and potential for future sales growth.
SHANGHAI, China and CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the company's senior management team will participate in the following investor conferences in September 2023:
Zai Lab Limited's recent clinical study results and partnerships demonstrate its commitment to innovation and product development, positioning it as a strong investment prospect in the pharmaceutical industry. The company's partnership with MediLink and the development of YL212, a next-generation antibody-drug conjugate, further strengthen its oncology pipeline and lung cancer product line. Despite a net loss, Zai Lab retains a substantial amount of cash and cash equivalents, short-term investments, and restricted cash, placing it in a strong position for further expansion and investment opportunities.
Zai Lab collaborated with NovoCure on a study to treat non-small cell lung cancer. There were some concerns about the validity of the study.
Zai Lab will soon launch a handful of new medicines in China. It's also seeking approval for many of its therapies in the U.S. The company also has enough cash to survive even if some of its clinical trials fail.
What type of business is Zai Lab Limited?
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
What sector is Zai Lab Limited in?
Zai Lab Limited is in the Healthcare sector
What industry is Zai Lab Limited in?
Zai Lab Limited is in the Biotechnology industry
What country is Zai Lab Limited from?
Zai Lab Limited is headquartered in China
When did Zai Lab Limited go public?
Zai Lab Limited initial public offering (IPO) was on 20 September 2017
What is Zai Lab Limited website?
https://www.zailaboratory.com
Is Zai Lab Limited in the S&P 500?
No, Zai Lab Limited is not included in the S&P 500 index
Is Zai Lab Limited in the NASDAQ 100?
No, Zai Lab Limited is not included in the NASDAQ 100 index
Is Zai Lab Limited in the Dow Jones?
No, Zai Lab Limited is not included in the Dow Jones index
When does Zai Lab Limited report earnings?
The next expected earnings date for Zai Lab Limited is 07 August 2024